Clinical Trials Logo

Allergy to Cats clinical trials

View clinical trials related to Allergy to Cats.

Filter by:
  • None
  • Page 1

NCT ID: NCT06069063 Not yet recruiting - Allergy to Cats Clinical Trials

Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge

Start date: March 5, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the hypothesis that pre-treatment with a nasal dose of Zafirlukast works well in blocking the signs and symptoms of cat dander in patients sensitive to cat dander. The main question it aims to answer is: • What is the difference in the symptoms of patients pre-treated with Zafirlukast and patients treated with a placebo (a look-alike substance that contains no active drug) when exposed to cat dander? Participants will screened to see if they qualify for the study based on their reaction to being exposed to cat dander and medical history. If they qualify, they will make two more visits to the allergy center, where they will be pre-treated with either Zafirlukast or a placebo and exposed to cat dander, then observed for four hours. Participants will - First be screened for their medical history, the medication they take, and other factors to see if they qualify for the study. - Participants will then be exposed to a fixed dose of cat dander to test their baseline change in TNSS. Some patients may need to return for a higher dose of cat dander. - On the next visit, some participants will be pre-treated with Zafirlukast and the rest with a placebo, then they will be exposed to cat dander. Their symptoms will be observed. - On the final visit, participants who were pre-treated with Zafirlukast on their last visit will be given a placebo. Participants who were pre-treated with a placebo on their last visit will be given Zafirlukast. All participants will then be exposed to cat dander and their symptoms will be observed.

NCT ID: NCT05455749 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Effect of holoBLG on Cat Allergic Patients

Start date: October 4, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the antigen-unspecific effect of a 3 months supplementation with a food for special medical purposes (FSMP) in form of a lozenge containing beta-lactoglobulin (BLG), iron, retinoic acid, zinc and polyphenols (holo-BLG) in patients with allergic rhinoconjunctivitis caused by cat (hair/dander) and the associated symptoms (symptom type and severity) during exposure to cat allergen in an Allergen Exposure Chamber (AEC).

NCT ID: NCT04678063 Completed - Allergy Clinical Trials

Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With Asthma

Start date: April 10, 2017
Phase: N/A
Study type: Interventional

This is a randomized, double blind, cross-over study designed to determine the concentration of airborne cat allergen inducing bronchial response in asthmatic subjects allergic to cat, during allergen exposures in the Alyatec environmental exposure chamber (EEC). The study was also designed to validate the specificity of the asthmatic reaction induced by exposure to airborne cat allergen in Alyatec EEC.

NCT ID: NCT04619017 Active, not recruiting - Allergic Rhinitis Clinical Trials

Airway Immune Response to Allergens (Use Lay Language Here)

Start date: October 28, 2021
Phase: Phase 1
Study type: Interventional

Most asthma is allergic in origin. The purpose of this study is to better understand the airway immune response to inhaled allergens in order to identify factors that promote asthma.

NCT ID: NCT04442932 Withdrawn - Allergy Clinical Trials

abioSCOPE IgE Assay to Aid in the Diagnosis of Allergies

Start date: November 15, 2020
Phase:
Study type: Observational

This is a multicenter, prospective, observational study designed to determine the clinical sensitivity and specificity of the Abionic IVD CAPSULE Allergic Asthma panel performed on Abionic's abioSCOPE device using K3-EDTA anticoagulated plasma samples from atopic and non-atopic pediatric and adult patients. Patients' sensitization determined with the abioSCOPE will be compared to the clinical assessment of allergy.

NCT ID: NCT04401631 Withdrawn - Allergy Clinical Trials

Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

Start date: November 2020
Phase:
Study type: Observational

This is a multicenter, prospective, observational study to evaluate the analytical performance of the Abionic IgE Multi-Allergen Test Panel on the abioSCOPE® device in a U.S. point-of-care environment within a clinical laboratory operating under a CLIA certificate for tests of moderate complexity. The study will assess point-of-care ('external') precision, sample type comparison and correlation with a reference method (Phadia Laboratory System, ThermoFisher Scientific).

NCT ID: NCT00620880 Completed - Allergy to Cats Clinical Trials

IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy

Start date: September 2005
Phase: N/A
Study type: Observational

Primary objective of the trial: To determine at which concentration the fusion protein MAT Fel d1 degranulates basophils of cat dander allergic patients, in comparison to a cat dander extract and to Fel d1 alone